Rictor is an independent prognostic factor for endometrial carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 2068-2078

  Wen, Shan Yun ^a,b   Li, Chang Hua ^c   Zhang, Yan Li ^d   Bian, Yu Hai ^d   Ma, Li ^a   Ge, Qiu Lin ^a   Teng, Yin Cheng ^a   Zhang, Zhi Gang ^d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Songjiang People Hospital of Shanghai   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Endometrial carcinoma; Prognosis; Rictor

Indexed keywords

CARRIER PROTEIN; MESSENGER RNA; RICTOR PROTEIN, HUMAN; TUMOR MARKER;

BIOPSY; CANCER GRADING; CANCER STAGING; CARCINOMA; CHEMISTRY; CHI SQUARE DISTRIBUTION; ENDOMETRIUM TUMOR; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME; TUMOR INVASION; UPREGULATION;

BIOPSY; CARCINOMA; CARRIER PROTEINS; CHI-SQUARE DISTRIBUTION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84902440193     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kang S, Lee JM, Lee JK, Kim JW, Cho CH, Kim SM, Park SY, Park CY and Kim KT. How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study. J Gynecol Oncol 2012; 23: 251-256.
2. Geels YP, Pijnenborg JM, van den Berg-van Erp SH, Snijders MP, Bulten J and Massuger LF. Absolute depth of myometrial invasion in endometrial cancer is superior to the currently used cut-off value of 50%. Gynecol Oncol 2013; 129: 285-291.
3. Luomaranta A, Leminen A and Loukovaara M. Prediction of lymph node and distant metastasis in patients with endometrial carcinoma: a new model based on demographics, biochemical factors, and tumor histology. Gynecol Oncol 2013; 129: 28-32.
4. Laplante M and Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
5. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-175.
6. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-1302.
7. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH and Hung MC. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007; 130: 440-455.
8. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A and Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-1128.
9. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
10. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J and Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127: 125-137.
11. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA and Alessi DR. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 2007; 405: 513-522.
12. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell ED, Bally MB, Foster LJ and Dedhar S. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 2008; 68: 1618-1624.
13. He Y, Li D, Cook SL, Yoon MS, Kapoor A, Rao CV, Kenis PJA, Chen J and Wang F. Mammalian target of rapamycin and Rictor control neutrophil chemotaxis by regulating Rac/Cdc42 activity and the actin cytoskeleton. Mol Biol Cell 2013; 24: 3369-3380.
14. Carson RP, Fu C, Winzenburger P and Ess KC. Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex. Hum Mol Genet 2012; 22: 140-152.
15. Jia W, Sanders AJ, Jia G, Liu X, Lu R and Jiang WG. Expression of the mTOR pathway regulators in human pituitary adenomas indicates the clinical course. Anticancer Res 2013; 33: 3123-3131.
16. Balasubramanian S, Johnston RK, Moschella PC, Mani SK, Tuxworth WJ Jr and Kuppuswamy D. mTOR in growth and protection of hypertrophying myocardium. Cardiovasc Hematol Agents Med Chem 2009; 7: 52-63.
17. Agarwal NK, Chen CH, Cho H, Boulbès DR, Spooner E and Sarbassov DD. Rictor regulates cell migration by suppressing RhoGDI2. Oncogene 2012; 32: 2521-2526.
18. Guo Z, Zhou Y, Evers BM and Wang Q. Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells. Biochem Biophys Res Commun 2012; 418: 426-432.
19. Wu MJ, Chang CH, Chiu YT, Wen MC, Shu KH, Li JR, Chiu KY and Chen YT. Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin. Urol Oncol 2012; 30: 69-77.
20. Oshima R, Bashir T, Cloninger C, Artinian N, Anderson L, Bernath A, Holmes B, Benavides-Serrato A, Sabha N, Nishimura RN, Guha A and Gera J. Conditional Astroglial Rictor Overexpression Induces Malignant Glioma in Mice. PLoS One 2012; 7: 47741.
21. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K and Inazawa J. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 2011; 71: 5765-5778.
22. Kyprianou N, Oneyama C, Kito Y, Asai R, Ikeda JI, Yoshida T, Okuzaki D, Kokuda R, Kakumoto K, Takayama KI, Inoue S, Morii E and Okada M. MiR-424/503-Mediated Rictor Upregulation Promotes Tumor Progression. PLoS One 2013; 8: e80300.
23. Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, Cao W, Wei X, Cao X, Hao X and Zhang N. mTOR Complex Component Rictor Interacts with PKC and Regulates Cancer Cell Metastasis. Cancer Res 2010; 70: 9360-9370.
24. Kyprianou N, Gupta S, Hau AM, Beach JR, Harwalker J, Mantuano E, Gonias SL, Egelhoff TT and Hansel DE. Mammalian Target of Rapamycin Complex 2 (mTORC2) Is a Critical Determinant of Bladder Cancer Invasion. PLoS One 2013; 8: e81081.
25. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL and Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983, 1983. e1971-1911.
26. Uesugi A, Kozaki Ki, Tsuruta T, Furuta M, Morita KI, Imoto I, Omura K and Inazawa J. The Tumor Suppressive MicroRNA miR-218 Targets the mTOR Component Rictor and Inhibits AKT Phosphorylation in Oral Cancer. Cancer Res 2011; 71: 5765-5778.
27. Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, Susumu N, Aoki D and Inazawa J. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011; 71: 6450-6462.
28. Shiozawa T and Konishi I. Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. Int J Clin Oncol 2006; 11: 13-21.
29. Serrano I, McDonald PC, Lock FE and Dedhar S. Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT). Oncogene 2012; 32: 50-60.
30. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell ED, Bally MB, Foster LJ and Dedhar S. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 2008; 68: 1618-1624.
31. Hagan GN, Lin Y, Magnuson MA, Avruch J and Czech MP. A Rictor-Myo1c Complex Participates in Dynamic Cortical Actin Events in 3T3-L1 Adipocytes. Mol Cell Biol 2008; 28: 4215-4226.
32. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H and Arii S. Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg 2011; 253: 94-100.
33. Foster HA, Davies J, Pink RC, Turkcigdem S, Goumenou A, Carter DR, Saunders NJ, Thomas P and Karteris E. The human myometrium differentially expresses mTOR signalling components before and during pregnancy: Evidence for regulation by progesterone. J Steroid Biochem Mol Biol 2014; 139: 166-172.
34. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335: 640-649.
35. .
36. Maki Carl G, Im-aram A, Farrand L, Bae SM, Song G, Song YS, Han JY and Tsang BK. The mTORC2 Component Rictor Contributes to Cisplatin Resistance in Human Ovarian Cancer Cells. PLoS One 2013; 8: e75455.
37. Verreault M, Weppler SA, Stegeman A, Warburton C, Strutt D, Masin D and Bally MB. Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model. PLoS One 2013; 8: e59597.
38. Whiteman EL, Cho H and Birnbaum MJ. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 2002; 13: 444-451.
39. Wang CY, Kim HH, Hiroi Y, Sawada N, Salomone S, Benjamin LE, Walsh K, Moskowitz MA and Liao JK. Obesity Increases Vascular Senescence and Susceptibility to Ischemic Injury Through Chronic Activation of Akt and mTOR. Sci Signal 2009; 2: 11.
40. Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA and Bae-Jump VL. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecolc Oncol 2012; 125: 458-469.